香砂养胃丸联合替普瑞酮胶囊治疗慢性萎缩性胃炎的临床研究

目的探讨香砂养胃丸联合替普瑞酮胶囊治疗慢性萎缩性胃炎的临床疗效。方法选取2013年5月—2016年5月中国人民解放军第二五一医院收治的慢性萎缩性胃炎患者110例,随机分为对照组和治疗组,每组各55例。对照组口服替普瑞酮胶囊,50 mg/次,3次/d。治疗组在对照组基础上口服香砂养胃丸,9 g/次,2次/d。两组患者均治疗8周。观察两组的临床疗效,比较两组胃黏膜评分、生理健康总评分(PCS)、心理健康总评分(MCS)和血清炎症因子水平。结果治疗后,对照组和治疗组的总有效率分别为74.5%、92.7%,两组比较差异有统计学意义(P0.05)。治疗后,两组胃黏膜评分均显著降低,而PCS和MCS均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组TNF-α、IL-6和IL-8水平均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的下降程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论香砂养胃丸联合替普瑞酮胶囊治疗慢性萎缩性胃炎具有较好的临床疗效,能改善临床症状,降低炎症反应,提高生活质量,具有一定的临床推广应用价值。

Clinical study on Xiangsha Yangwei Pills combined with Teprenone Capsules in treatment of chronic atrophic gastritis

Objective To investigate the clinical effect of Xiangsha Yangwei Pills combined with Teprenone Capsules in treatment of chronic atrophic gastritis. Methods Patients (110 cases) with chronic atrophic gastritis in the 251 st Hospital of PLA from May 2013 to May 2016 were randomly divided into control and treatment groups, and each group had 55 cases. Patients in the control group were po administered with Teprenone Capsules, 50 mg/time, three times daily. Patients in the treatment group were po administered with Xiangsha Yangwei Pills on the basis of the control group, 9 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and gastric mucosal score, PCS, MCS, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.5%and 92.7%, respectively, and there was difference between two groups (P < 0.05). After treatment, gastric mucosal scores in two groups were significantly decreased, but PCS and MCS in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, TNF-α, IL-6, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xiangsha Yangwei Pills combined with Teprenone Capsules has clinical curative effect in treatment of chronic atrophic gastritis, can improve clinical symptoms, decrease inflammatory response, and increase quality of life, which has a certain clinical application value.